Lansoprazol Aurobindo

Lansoprazole, the active ingredient in Lansoprazol Aurobindo, is a proton pump inhibitor presented as an oral tablet for systemic use. It reduces gastric acid production and is employed in the management of acid‑related gastrointestinal conditions in adults. The medication is formulated for oral administration and is indicated for conditions where suppression of gastric acidity is required.

GNH USA supplies Lansoprazol Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to treat disorders related to excess stomach acid.

- Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing by lowering gastric acidity. - Helicobacter pylori eradication regimens: enhances the effectiveness of antibiotic combinations. - Prevention of NSAID‑induced gastric ulcers: protects the gastric mucosa in patients receiving non‑steroidal anti‑inflammatory drugs.

Lansoprazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools occurring intermittently. - Nausea: occasional feeling of queasiness. - Abdominal pain: discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridium difficile infection: severe diarrhea with abdominal cramping. - Low magnesium levels (hypomagnesemia): muscle weakness, irregular heartbeat. - Elevated liver enzymes: possible hepatitis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Interstitial nephritis: kidney inflammation presenting with fever and rash.

When prescribing lansoprazole, clinicians should consider several safety precautions.

- Renal or hepatic impairment: assess function before initiating therapy. - Elderly patients: start with the lowest effective dose and monitor response. - Magnesium deficiency: monitor serum magnesium during prolonged use. - Rebound acid hypersecretion: avoid abrupt discontinuation after long‑term therapy. - Concomitant medications affecting gastric pH: review for potential interactions. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lansoprazole can affect the pharmacokinetics of other medicines.

Major Interactions (Avoid): - Atazanavir: reduced absorption leading to therapeutic failure. - Nelfinavir: decreased plasma concentrations. - Rilpivirine: lowered exposure compromising antiviral effect. - Clopidogrel: reduced activation, decreasing antiplatelet efficacy. - Methotrexate: increased serum levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer monitoring. - Digoxin: modest rise in serum concentration. - Ketoconazole: decreased absorption, may need dose adjustment. - Iron salts: reduced iron uptake, separate dosing times. - Vitamin B12: long‑term use may impair absorption, monitor levels.